Citigroup Maintains Buy on Ascendis Pharma, Raises Price Target to $207
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst David Lebowitz has maintained a Buy rating on Ascendis Pharma and increased the price target from $178 to $207.
September 17, 2024 | 3:21 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Citigroup analyst David Lebowitz has maintained a Buy rating on Ascendis Pharma and increased the price target from $178 to $207, indicating a positive outlook for the stock.
The increase in the price target from $178 to $207 by Citigroup suggests a strong positive outlook for Ascendis Pharma. This is likely to boost investor confidence and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100